Editor's Favorite: Arora et al present "99mTc-Methionine Hybrid SPECT/CT for Detection of Recurrent Glioma: Comparison With 18F-FDG PET/CT and Contrast-Enhanced MRI". Forty-four participants with previously treated glioma and clinical suspicion of recurrence were prospectively examined. Of these 44 participants, 39 underwent 99mTc-methionine SPECT/CT, 18F-FDG PET/CT, and CeMRI of the brain. Positive predictive value and negative predictive value for 99mTc-methionine SPECT/CT, 18F-FDG PET/CT, and CeMRI were 95.6% and 56.2%, 92.3% and 61.5%, and 79.4% and 42.9%, respectively. Sensitivity and specificity for the 3 modalities were 75.9% and 90%, 82.8% and 80%, and 87.1% and 30%. Specificity of 99mTc-methionine SPECT/CT was significantly higher than that of CeMRI (P < 0.0001) but not of 18F-FDG PET/CT (P = 0.36). No significant difference was seen between the modalities for sensitivity and accuracy. Authors concluded that 99mTc-methionine is a promising tracer for detection of recurrent glioma. Diagnostic values of 99mTc-methionine SPECT/CT are similar to 18F-FDG, although it is more specific than CeMRI. 99mTc-Methionine SPECT/CT may be a helpful alternative to 11C PET/CT.